Antimicrobial Activity of Daptomycin Tested Against Gram-Positive Strains Collected in European Hospitals: Results from 7 Years of Resistance Surveillance (2003-2009)

Página do item simplificado
dc.contributor.authorSader, Helio Silva [UNIFESP]
dc.contributor.authorFarrell, D. J.
dc.contributor.authorJones, R. N.
dc.contributor.institutionJMI Labs Inc
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionTufts Univ
dc.date.accessioned2018-06-15T17:53:11Z
dc.date.available2018-06-15T17:53:11Z
dc.date.issued2011-08-01
dc.description.abstractDaptomycin is a cyclic lipopeptide approved by the European Medicines Agency (EMEA) for the treatment of complicated skin and soft tissue infections (cSSTI) and Staphylococcus aureus bacteremia and endocarditis. We evaluated the in vitro activity of daptomycin and comparators tested against clinical isolates from European hospitals over a 7-year period (2003-2009). A total of 36,769 consecutive isolates were collected in 34 medical centers located in 13 European countries, Turkey and Israel. The collection included S. aureus (18,352; 27.2% oxacillin-resistant [MRSA]); coagulase-negative staphylococci (CoNS; 6,874), Enterococcus spp. (7,241; 9.4% vancomycin-resistant), beta-hemolytic (3,009), viridans group streptococci (1,176), and Streptococcus bovis/gallolyticus (107). The organisms were isolated mainly from patients with bloodstream infection (56%) or cSSTI (23%). Daptomycin was very active against S. aureus and CoNS (MIC(50/90), 0.25/0.5 mg/L for both organisms), and its activity was not adversely influenced by oxacillin resistance. All Enterococcus faecalis strains were susceptible to daptomycin (MIC(50/90), 1/1 mg/L). Daptomycin (MIC(50/90), 2/2 mg/L; 100.0% susceptible) and linezolid (MIC(50/90), 1/2 mg/L; 99.7% susceptible) were the most active agents tested against vancomycin-resistant E. faecium. Vancomycin-resistant and -susceptible enterococcal strains were equally susceptible to daptomycin. Daptomycin was also active against beta-hemolytic streptococci (MIC(50/90), 0.06/0.25 mg/L; 100.0% susceptible), viridans group streptococci (MIC(50/90), 0.25/0.5 mg/L; 99.8% susceptible) and S. bovis (MIC(50/90), 0.06/0.12 mg/L; 100.0% susceptible). In summary, daptomycin was very potent against this large collection (36,769) of Gram-positive organisms isolated in European hospitals, and its activity remained stable across the 7-year period evaluated (2003-2009), using reference methods and interpretive criteria. Decreases in daptomycin potency were not observed since EMEA approval and widespread clinical use, and emerging resistance to other compounds did not adversely influence daptomycin activity against contemporary Gram-positive species.en
dc.description.affiliationJMI Labs Inc, N Liberty, IA 52317 USA
dc.description.affiliationUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationTufts Univ, Sch Med, Boston, MA 02111 USA
dc.description.affiliationUnifespUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipAchaogen
dc.description.sponsorshipAffinium
dc.description.sponsorshipAstellas
dc.description.sponsorshipAstraZeneca
dc.description.sponsorshipBayer
dc.description.sponsorshipCempra
dc.description.sponsorshipCerexa
dc.description.sponsorshipCubist
dc.description.sponsorshipDaiichi
dc.description.sponsorshipEnanta
dc.description.sponsorshipForest
dc.description.sponsorshipFuriex
dc.description.sponsorshipGlaxoSmithKline
dc.description.sponsorshipJohnson & Johnson (Ortho McNeil)
dc.description.sponsorshipMeiji Seika
dc.description.sponsorshipNabriva
dc.description.sponsorshipNovartis
dc.description.sponsorshipOptimer
dc.description.sponsorshipOrdway
dc.description.sponsorshipParatek
dc.description.sponsorshipPfizer
dc.description.sponsorshipPolyphor
dc.description.sponsorshipPPD
dc.description.sponsorshipShionogi
dc.description.sponsorshipTheravance
dc.description.sponsorshipWyeth
dc.format.extent200-206
dc.identifierhttp://dx.doi.org/10.1179/joc.2011.23.4.200
dc.identifier.citationJournal Of Chemotherapy. Florence: Esift Srl, v. 23, n. 4, p. 200-206, 2011.
dc.identifier.doi10.1179/joc.2011.23.4.200
dc.identifier.issn1120-009X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/44246
dc.identifier.wosWOS:000294584600002
dc.language.isoeng
dc.publisherEsift Srl
dc.relation.ispartofJournal Of Chemotherapy
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectDaptomycinen
dc.subjectEuropeen
dc.subjectresistanceen
dc.subjectsurveillanceen
dc.titleAntimicrobial Activity of Daptomycin Tested Against Gram-Positive Strains Collected in European Hospitals: Results from 7 Years of Resistance Surveillance (2003-2009)en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos